HLA-DRB1, major histocompatibility complex, class II, DR beta 1, 3123
N. diseases: 1018; N. variants: 185
Source: ALL
Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 0.040 | 6 | 32605248 | intergenic variant | A/G | snv |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | ||||||||
|
1.000 | 0.040 | 6 | 32583926 | intron variant | G/T | snv |
|
Mental Disorders | 0.700 | 1.000 | 1 | 2017 | 2017 | ||||||||
|
1.000 | 0.040 | 6 | 32583926 | intron variant | G/T | snv |
|
Mental Disorders | 0.700 | 1.000 | 1 | 2017 | 2017 | ||||||||
|
1.000 | 0.040 | 6 | 32596904 | intergenic variant | A/C | snv | 0.34 |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
1.000 | 0.040 | 6 | 32604184 | intergenic variant | T/C | snv | 0.13 |
|
Nervous System Diseases | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||||
|
0.925 | 0.120 | 6 | 32602624 | intergenic variant | G/A | snv | 0.27 |
|
Immune System Diseases; Nervous System Diseases | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.925 | 0.120 | 6 | 32602624 | intergenic variant | G/A | snv | 0.27 |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.925 | 0.120 | 6 | 32602624 | intergenic variant | G/A | snv | 0.27 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Skin and Connective Tissue Diseases; Immune System Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Nutritional and Metabolic Diseases; Immune System Diseases; Endocrine System Diseases | 0.700 | 1.000 | 1 | 2007 | 2007 | |||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Infections | 0.700 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Endocrine System Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
0.742 | 0.400 | 6 | 32602623 | intergenic variant | T/C | snv | 0.27 |
|
Skin and Connective Tissue Diseases | 0.700 | 1.000 | 1 | 2010 | 2010 | |||||||
|
1.000 | 0.040 | 6 | 32602575 | intergenic variant | G/A | snv | 0.47 |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
6 | 32602640 | intergenic variant | A/C | snv | 0.13 |
|
0.700 | 1.000 | 1 | 2018 | 2018 | ||||||||||
|
1.000 | 0.040 | 6 | 32606133 | intergenic variant | C/T | snv | 0.22 |
|
Hemic and Lymphatic Diseases | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||||
|
6 | 32606583 | intergenic variant | C/T | snv | 0.30 |
|
0.700 | 1.000 | 1 | 2018 | 2018 | ||||||||||
|
6 | 32606583 | intergenic variant | C/T | snv | 0.30 |
|
0.700 | 1.000 | 1 | 2018 | 2018 | ||||||||||
|
1.000 | 0.040 | 6 | 32597688 | intergenic variant | G/A;C;T | snv |
|
Mental Disorders | 0.700 | 1.000 | 1 | 2017 | 2017 | ||||||||
|
1.000 | 0.040 | 6 | 32597688 | intergenic variant | G/A;C;T | snv |
|
Mental Disorders | 0.700 | 1.000 | 1 | 2017 | 2017 | ||||||||
|
6 | 32606581 | intergenic variant | G/A | snv | 0.20 |
|
Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||||||
|
6 | 32591705 | upstream gene variant | C/A;T | snv |
|
0.700 | 1.000 | 1 | 2018 | 2018 | |||||||||||
|
6 | 32591976 | upstream gene variant | T/C | snv | 0.12 |
|
Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 0.700 | 1.000 | 1 | 2018 | 2018 |